ATE321537T1 - Pharmazeutische zubereitung enthaltend doxazosin - Google Patents

Pharmazeutische zubereitung enthaltend doxazosin

Info

Publication number
ATE321537T1
ATE321537T1 AT02291474T AT02291474T ATE321537T1 AT E321537 T1 ATE321537 T1 AT E321537T1 AT 02291474 T AT02291474 T AT 02291474T AT 02291474 T AT02291474 T AT 02291474T AT E321537 T1 ATE321537 T1 AT E321537T1
Authority
AT
Austria
Prior art keywords
doxazosine
pharmaceutical preparation
preparation containing
doxazosin
core
Prior art date
Application number
AT02291474T
Other languages
English (en)
Inventor
Pawan Seth
Original Assignee
Cimex Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cimex Pharma Ag filed Critical Cimex Pharma Ag
Application granted granted Critical
Publication of ATE321537T1 publication Critical patent/ATE321537T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT02291474T 2001-09-14 2002-06-13 Pharmazeutische zubereitung enthaltend doxazosin ATE321537T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/953,072 US20030059467A1 (en) 2001-09-14 2001-09-14 Pharmaceutical composition comprising doxasozin

Publications (1)

Publication Number Publication Date
ATE321537T1 true ATE321537T1 (de) 2006-04-15

Family

ID=25493537

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02291474T ATE321537T1 (de) 2001-09-14 2002-06-13 Pharmazeutische zubereitung enthaltend doxazosin

Country Status (8)

Country Link
US (1) US20030059467A1 (de)
EP (1) EP1293196B1 (de)
AT (1) ATE321537T1 (de)
CY (1) CY1106084T1 (de)
DE (1) DE60212734T2 (de)
DK (1) DK1293196T3 (de)
ES (1) ES2259698T3 (de)
PT (1) PT1293196E (de)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
US20040162320A1 (en) * 2003-02-14 2004-08-19 Pawan Seth Solid composition containing nisoldipine a mixture of polyethylene oxides and an antioxidant
CN100391459C (zh) * 2003-05-26 2008-06-04 沈阳药科大学 甲磺酸多沙唑嗪缓释制剂
US20070048228A1 (en) 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
US8075872B2 (en) 2003-08-06 2011-12-13 Gruenenthal Gmbh Abuse-proofed dosage form
DE102004032051A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten, festen Darreichungsform
DE102005005446A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Bruchfeste Darreichungsformen mit retardierter Freisetzung
DE10361596A1 (de) 2003-12-24 2005-09-29 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
DE10336400A1 (de) 2003-08-06 2005-03-24 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
EP1680078A2 (de) * 2003-10-17 2006-07-19 Ranbaxy Laboratories, Ltd. Orale matrixformulierungen von doxazosin
DE102004032049A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
DE102005005449A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
KR101366764B1 (ko) * 2005-05-31 2014-02-25 주식회사 씨티씨바이오 메실산독사조신 서방정의 제조방법
DE102007011485A1 (de) 2007-03-07 2008-09-11 Grünenthal GmbH Darreichungsform mit erschwertem Missbrauch
CA2713128C (en) 2008-01-25 2016-04-05 Gruenenthal Gmbh Pharmaceutical dosage form
AU2009243681B2 (en) 2008-05-09 2013-12-19 Grunenthal Gmbh Process for the preparation of an intermediate powder formulation and a final solid dosage form under usage of a spray congealing step
CN102639118B (zh) 2009-07-22 2015-07-29 格吕伦塔尔有限公司 氧化稳定的抗干扰剂型
KR101738369B1 (ko) 2009-07-22 2017-05-22 그뤼넨탈 게엠베하 핫 멜트 압출된 제어 방출 투여형
TWI516286B (zh) 2010-09-02 2016-01-11 歌林達股份有限公司 含陰離子聚合物之抗破碎劑型
BR112013005194A2 (pt) 2010-09-02 2016-05-03 Gruenenthal Gmbh forma de dosagem resistente à violação compreendendo sal inorgânico
CN102058555A (zh) * 2011-01-13 2011-05-18 北京汇诚瑞祥医药技术有限公司 一种多沙唑嗪控释片
EA201400172A1 (ru) 2011-07-29 2014-06-30 Грюненталь Гмбх Устойчивая к разрушению таблетка, которая обеспечивает немедленное высвобождение лекарственного средства
BR112014001091A2 (pt) 2011-07-29 2017-02-14 Gruenenthal Gmbh comprimido resistente à adulteração que fornece liberação imediata do fármaco
MX356421B (es) 2012-02-28 2018-05-29 Gruenenthal Gmbh Forma de dosificacion resistente a la manipulacion indebida que comprende un compuesto farmacologicamente activo y un polimero anionico.
EP2838512B1 (de) 2012-04-18 2018-08-22 Grünenthal GmbH Fälschungssichere und dose dumping sichere pharmazeutische darreichungsform
US10064945B2 (en) 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
EP3003279A1 (de) 2013-05-29 2016-04-13 Grünenthal GmbH Manipulationssichere darreichungsform mit einem oder mehreren partikeln
US9737490B2 (en) 2013-05-29 2017-08-22 Grünenthal GmbH Tamper resistant dosage form with bimodal release profile
BR112016000194A8 (pt) 2013-07-12 2019-12-31 Gruenenthal Gmbh forma de dosagem resistente à violação contendo o polímero de acetato de etileno-vinila
EP3073994A1 (de) 2013-11-26 2016-10-05 Grünenthal GmbH Herstellung einer pulverförmigen pharmazeutischen zusammensetzung mittels kryogenen mahlens
WO2015173195A1 (en) 2014-05-12 2015-11-19 Grünenthal GmbH Tamper resistant immediate release capsule formulation comprising tapentadol
CN104224756A (zh) * 2014-09-26 2014-12-24 天津市聚星康华医药科技有限公司 一种甲磺酸多沙唑嗪口腔速溶膜及其制备方法
WO2016170097A1 (en) 2015-04-24 2016-10-27 Grünenthal GmbH Tamper-resistant dosage form with immediate release and resistance against solvent extraction
JP2018526414A (ja) 2015-09-10 2018-09-13 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 乱用抑止性の即放性製剤を用いた経口過剰摂取に対する保護

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4765989A (en) * 1983-05-11 1988-08-23 Alza Corporation Osmotic device for administering certain drugs
GB9523752D0 (en) * 1995-11-21 1996-01-24 Pfizer Ltd Pharmaceutical formulations

Also Published As

Publication number Publication date
EP1293196A2 (de) 2003-03-19
CY1106084T1 (el) 2011-06-08
PT1293196E (pt) 2006-05-31
ES2259698T3 (es) 2006-10-16
DE60212734T2 (de) 2006-11-09
DE60212734D1 (de) 2006-08-03
EP1293196A3 (de) 2004-01-02
US20030059467A1 (en) 2003-03-27
EP1293196B1 (de) 2006-03-29
DK1293196T3 (da) 2006-07-17

Similar Documents

Publication Publication Date Title
ATE321537T1 (de) Pharmazeutische zubereitung enthaltend doxazosin
HUP0402566A3 (en) C-5 modified indazolylamino pyrrolotriazines, their use and pharmaceutical compositions containing them
GEP20063741B (en) Nonaryl-Heterocyclic NMDA/NR2B Antagonists
NO324227B1 (no) Cyclopropyl-kondenserte pyrrolidin-baserte forbindelser, farmasoytiske blandinger og kombinasjoner inneholdende slike samt anvendelse av slike for fremstilling av medikamenter for behandling av sykdommer
NO973922D0 (no) Nye taxoider, deres fremstilling og farmasöytiske preparater inneholdende forbindelsene
HUP0401783A3 (en) 3,4-di-substituted cyclobutene-1,2-diones as cxc-chemokine receptor ligands, their use and pharmaceutical compositions containing them
TW200505406A (en) Pharmaceutical compositions comprising a basic respectively acidic drug compound, a surfactant and a physiologically tolerable water-soluble acid respectively base
MA26129A1 (fr) Melange insecticide contenant de la gamma-cyhalothrine
ATE289640T1 (de) Amidofunktionelle aminopolydiorganosiloxane
EE05183B1 (et) Asabitsklilised hendid, nende valmistamine ja kasutamine ravimitena ning neid sisaldav farmatseutiline kompositsioon
EA200300081A1 (ru) Гидрогель-управляемая лекарственная форма
DE60209929D1 (de) Succinate des 5,8,14-triazatetracycloä10.3.1.0 2,11 .0 4,9 ü-hexadeca-2(11),3,5,7,9,-pentaens und pharmazeutische zusammensetzungen
DE60219051D1 (de) Pyrimidonverbindungen und pharmazeutische zusammensetzungen, die diese enthalten
HUP0400179A3 (en) 2,5-diarylpyrazines, 2,5-diarylpyridines and 2,5-diarylpyrimidines, their use and pharmaceutical compositions containing them
EE200300537A (et) Meetod madalaannuselise farmatseutilise kompositsiooni tootmiseks
ATE252377T1 (de) Kontrolliert freisetzende pharmazeutische zusammensetzung mit tilidinmesylat als wirkstoff
DE60211183D1 (de) Pharmazeutische zusammensetzung enthaltend lumiracoxib
ATE350016T1 (de) Bicalutamid enthaltende pharmazeutische zusammensetzung
HUP0303469A3 (en) Phtalazinon-derivatives, their use and pharmaceutical compositions containing them
YU82693A (sh) Farmaceutske formulacije disulfonil metana i novi disulfonil metani
EA200400343A1 (ru) Композиция с контролируемым высвобождением кларитромицина или тинидазола
BR0212195A (pt) Composições contendo pectina e ácido ascórbico
AU2002238673A1 (en) Human adrenomedullin-specific antibody, pharmaceutical composition containing same, therapeutic uses thereof
MXPA02012015A (es) Ligandos de receptores para integrinas.
DE10291905D2 (de) Pharmazeutische Zusammensetzung

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1293196

Country of ref document: EP

EEIH Change in the person of patent owner